Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Mereo BioPharma Group plc - Sponsored ADR (MREO) had Return on Tangible Equity of -24.67% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-7.00M |
|
-- |
|
-- |
|
$7.03M |
|
$-7.03M |
|
$0.03M |
|
$-7.00M |
|
$-7.00M |
|
$-7.00M |
|
$-7.00M |
|
$-7.00M |
|
$-7.00M |
|
$-7.03M |
|
$-6.87M |
|
160.71M |
|
160.71M |
|
$-0.05 |
|
$-0.05 |
|
| Balance Sheet Financials | |
$33.40M |
|
$0.05M |
|
$1.31M |
|
$34.71M |
|
$5.68M |
|
-- |
|
$0.39M |
|
$6.06M |
|
$28.65M |
|
$28.40M |
|
$28.65M |
|
159.62M |
|
| Cash Flow Statement Financials | |
$-10.36M |
|
$-0.30M |
|
-- |
|
$40.99M |
|
$30.12M |
|
$-10.87M |
|
$2.92M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.88 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.36M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-24.45% |
|
|
Return on Tangible Equity |
-24.67% |
-20.18% |
|
-24.45% |
|
$0.18 |
|
$-0.06 |
|
$-0.06 |
|